Abstract
We evaluated the potential use of intraoperative gelatin matrix hemostatic sealant (GMHS; FloSeal; Baxter Healthcare) embedded with macrophages (Mφ) transduced with murine interleukin (IL)-12 recombinant adenoviral vector (G/Mφ/AdmIL-12) for prevention of recurrence of prostate cancer following radical prostatectomy. Application of G/Mφ/AdmIL-12 resulted in significant suppression of tumor growth and spontaneous lung metastases, a statistically significant survival advantage of the G/Mφ/AdmIL-12-treated animals, more efficient trafficking of Mφ to lymph nodes draining from the prostate and generation of systemic natural killer cell activity and tumor-specific cytolytic T lymphocyte responses compared to the controls in a preclinical mouse model of residual prostate cancer. Our data recommend this treatment as a novel adjuvant for prevention of local recurrence of prostate cancer following radical prostatectomy.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fpcan.2008.57/MediaObjects/41391_2009_Article_BFpcan200857_Fig1_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fpcan.2008.57/MediaObjects/41391_2009_Article_BFpcan200857_Fig2_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fpcan.2008.57/MediaObjects/41391_2009_Article_BFpcan200857_Fig3_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fpcan.2008.57/MediaObjects/41391_2009_Article_BFpcan200857_Fig4_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fpcan.2008.57/MediaObjects/41391_2009_Article_BFpcan200857_Fig5_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fpcan.2008.57/MediaObjects/41391_2009_Article_BFpcan200857_Fig6_HTML.jpg)
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC . Natural history of progression after PSA elevation following radical prostatectomy. Jama 1999; 281: 1591–1597.
Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE et al. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer 2007; 110: 2628–2639.
Timme TL, Fujita N, Wang HY, Naruishi K, Kadmon D, Amato RJ et al. Cytokine Gene Therapy for Genitourinary Cancer. Humana Press: Totowa, 2006.
Miles BJ, Shalev M, Aguilar-Cordova E, Timme TL, Lee HM, Yang G et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 2001; 12: 1955–1967.
Ayala G, Wheeler TM, Shalev M, Thompson TC, Miles B, Aguilar-Cordova E et al. Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol 2000; 31: 866–870.
Bingle L, Brown NJ, Lewis CE . The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254–265.
Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC . Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000; 60: 5857–5861.
Satoh T, Saika T, Ebara S, Kusaka N, Timme TL, Yang G et al. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res 2003; 63: 7853–7860.
Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90: 2541–2548.
Nasu Y, Bangma CH, Hull GW, Lee HM, Hu J, Wang J et al. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Therapy 1999; 6: 338–349.
Oz MC, Cosgrove III DM, Badduke BR, Hill JD, Flannery MR, Palumbo R et al. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. The Fusion Matrix Study Group. Ann Thorac Surg 2000; 69: 1376–1382.
Reuthebuch O, Lachat ML, Vogt P, Schurr U, Turina M . FloSeal: a new hemostyptic agent in peripheral vascular surgery. Vasa 2000; 29: 204–206.
Ellegala DB, Maartens NF, Laws Jr ER . Use of FloSeal hemostatic sealant in transsphenoidal pituitary surgery: technical note. Neurosurgery 2002; 51: 513–515; discussion 515–516.
Ahlering TE, Eichel L, Chou D, Skarecky DW . Feasibility study for robotic radical prostatectomy cautery-free neurovascular bundle preservation. Urology 2005; 65: 994–997.
Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL . Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996; 7: 1995–2002.
Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA et al. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 1995; 10: 869–879.
Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61: 3882–3885.
Lee HM, Timme TL, Thompson TC . Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res 2000; 60: 1927–1933.
Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223–1230.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tabata, K., Watanabe, M., Naruishi, K. et al. Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. Prostate Cancer Prostatic Dis 12, 301–309 (2009). https://doi.org/10.1038/pcan.2008.57
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2008.57
- Springer Nature Limited